Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, cancer, systemic lupus erythematosus, rheumatoid arthritis and drug-induced rash.
Shanghai Pharmaceuticals Holding Co. Ltd. has disclosed aza-ergoline derivatives acting as dopamine D2 receptor and/or D3 receptor agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, erectile dysfunction, substance abuse and dependence, restless legs syndrome, schizophrenia, Parkinson’s and Alzheimer’s disease, among others.
Shanghai Pharmaceuticals Holding Co. Ltd. has described quinazoline compounds acting as TNF-α and/or IL-6 and/or IL-1β production inhibitors reported to be useful for the treatment of cancer, asthma, malaria, viral infections, autoimmune diseases, cardiovascular disorders, chronic obstructive pulmonary disease (COPD) and transplant rejection.
Shanghai Pharmaceutical Holding Co. Ltd. out-licensed global rights of its antitumor small-molecule chemical drug, SPH-6162, to U.S.-based Huya Bioscience International LLC in a deal worth up to $292.5 million, plus a sales commission of 3% to 6%.
Shanghai Pharmaceutical Holding Co. Ltd. out-licensed global rights of its antitumor small-molecule chemical drug, SPH-6162, to U.S.-based Huya Bioscience International LLC in a deal worth up to $292.5 million, plus a sales commission of 3% to 6%.
